Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

When Oncology NDAs Fail, Clinical Benefit Is Often In Question

This article was originally published in The Pink Sheet Daily

Executive Summary

Pre-submission meetings can address questions of clinically meaningful endpoints and appropriate subgroups, avoiding negative regulatory outcomes, FDA analysis suggests.

You may also be interested in...



A Cautious Guide To The Interpretation Of Clinical Trials From NEJM

Determining the success or failure of a randomized trial requires looking beyond the p-value for the primary endpoint, review articles in The New England Journal of Medicine urge.

REMS, ‘Breakthrough’ Meetings Get ‘Type B’ Tag In Revised FDA Guidance

In other modifications, FDA tells sponsors seeking Type A meetings – the most urgent category – that data packages must accompany the request.

Accelerated Approval For Bluebird’s Skysona Gives Teeth To US FDA Data Questions

Two required confirmatory studies will bolster application that relied on historical controls for orphan neurodegenerative disease.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS078517

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel